Hosomi, Yukio
Tokyo Metropolitan Komagome Hospital
2 papers on CoChatORCID 0000-0002-3849-5905
Most cited papers
- Verified
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
Seto, T., Kato, T., Nishio, M., Goto, K., Atagi, S., Hosomi, Y., Yamamoto, N., Hida, T., Maemondo, M., Nakagawa, K., et al. (2014) · The Lancet Oncology
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Cited by 750
- Verified
The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung Cancer
Hakozaki, T., Richard, C., Elkrief, A., Hosomi, Y., Benlaïfaoui, M., Mimpen, I., Terrisse, S., Derosa, L., Zitvogel, L., Routy, B., et al. (2020) · Cancer Immunology Research
Cancer Immunotherapy and BiomarkersGut microbiota and health
Cited by 316
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free